The global HIV/AIDS crisis produced one of the most consequential confrontations between patent rights and public health. As antiretroviral therapies (ARTs) that could transform HIV from a death sentence into a manageable chronic condition became available in the late 1990s, their patent-protected prices placed them beyond the reach of the populations that needed them most. Esteban Burrone examined the Medicines Patent Pool (MPP), established in 2010, as an institutional innovation designed to resolve this tension through voluntary licensing rather than compulsory measures.
The Access Crisis
By the early 2000s, first-generation antiretroviral therapies were available at prices exceeding $10,000 per patient per year in developing countries where average annual incomes were a fraction of that amount. Generic manufacturers in India and elsewhere had demonstrated that the same drugs could be produced for under $100 per year, but patent protection in many countries prevented these manufacturers from entering the market legally.
The international response included the 2001 Doha Declaration on TRIPS and Public Health, which affirmed countries’ right to use compulsory licensing for public health emergencies. Several nations — notably Brazil, Thailand, and South Africa — issued or threatened compulsory licenses for key ARTs. While effective in specific cases, compulsory licensing proved politically costly and difficult to implement at scale. The pharmaceutical industry viewed it as a threat to the patent system, and trade pressure from the United States and European Union discouraged its use.
The Pooled Licensing Model
The Medicines Patent Pool offered an alternative. Established by UNITAID, a global health initiative funded primarily by airline ticket levies, the MPP negotiated voluntary licenses with patent holders for essential medicines. These licenses were then sublicensed to generic manufacturers in developing countries, who paid royalties to the patent holder but could produce and sell the medicines at dramatically reduced prices.
The model drew on the concept of patent pools used in other industries, where multiple patent holders contribute their IP to a shared licensing framework. In the semiconductor and telecommunications industries, patent pools had long been used to manage the complexity of products that required licenses from dozens of patent holders. The MPP adapted this model for pharmaceuticals, where the challenge was not licensing complexity but rather the tension between patent-based pricing and public health needs.
Negotiating with Patent Holders
Burrone, who served as the MPP’s head of policy, described the negotiation dynamics in detail. The MPP’s leverage derived not from legal coercion but from the reputational and political costs of refusing to participate. A pharmaceutical company that declined to license essential medicines to the MPP risked public criticism, compulsory licensing by individual governments, and damage to its relationships with global health institutions that influenced procurement decisions worth billions of dollars.
The article documented the MPP’s first major agreement: a 2010 license from the U.S. National Institutes of Health for the antiretroviral drug darunavir. Subsequent agreements with Gilead Sciences, ViiV Healthcare, Bristol-Myers Squibb, and AbbVie expanded the pool’s coverage to include the most widely prescribed HIV treatments, as well as hepatitis C therapies and, later, tuberculosis drugs.
Impact on Drug Prices and Access
The pricing effects were substantial. MPP-licensed generic versions of tenofovir-based HIV regimens were available at a fraction of originator prices. Generic competition among sublicensees further drove prices down. Burrone presented data showing that MPP licenses had enabled the production of medicines reaching millions of patients in over 130 countries, with prices reduced by up to 90 percent compared to patented versions.
The quality dimension was equally important. MPP sublicenses included provisions requiring generic manufacturers to meet WHO prequalification standards or equivalent regulatory approval, addressing concerns that low-cost generics might compromise treatment quality. This approach connected to the broader debate about how regulatory frameworks for pharmaceutical competition balance price, quality, and innovation incentives.
Limitations and Critiques
The article acknowledged significant limitations. Voluntary licensing depended on patent holders’ willingness to participate, and some companies declined or imposed geographic restrictions that excluded middle-income countries where significant unmet need existed. The royalty terms in some agreements were criticized as excessive. And the model did not address the underlying question of whether pharmaceutical patent terms and pricing were appropriately calibrated to the needs of global health in the first place.
Critics from the access-to-medicines movement argued that the MPP legitimized an intellectual property regime that was fundamentally misaligned with public health objectives, providing a safety valve that reduced pressure for more structural reform. Burrone responded that the MPP was a practical tool that saved lives within the existing legal framework while more ambitious reforms were debated.
Expansion Beyond HIV
Since publication, the MPP has expanded significantly. Its role during the COVID-19 pandemic — negotiating licenses for nirmatrelvir (Paxlovid) and molnupiravir — demonstrated the model’s adaptability. The organization has also begun licensing long-acting injectable HIV treatments and cancer medicines, extending the voluntary licensing approach to new therapeutic areas. The institutional innovation Burrone described has become a permanent feature of the global health governance landscape.
Frequently Asked Questions
What is the Medicines Patent Pool?
The Medicines Patent Pool (MPP) is a United Nations-backed organization established in 2010 that negotiates voluntary licenses with pharmaceutical patent holders, then sublicenses those rights to generic manufacturers in developing countries. The goal is to increase access to affordable essential medicines.
How does voluntary licensing differ from compulsory licensing?
Voluntary licensing involves a negotiated agreement between the patent holder and licensee, typically including royalty payments and conditions. Compulsory licensing is imposed by a government without consent, as permitted under TRIPS Article 31. Voluntary licensing preserves commercial relationships and often includes technology transfer.
Has the Medicines Patent Pool been effective?
By 2024, MPP licenses had enabled the production of over 28 billion doses of generic medicines across more than 140 countries. The pooled licensing model reduced prices for key HIV treatments by up to 90 percent and has been credited with saving millions of lives.
Related articles: GATT/TRIPS and Development · Hatch-Waxman Pharmaceutical Patents · DNA Databases and Privacy · Commercial Speech and Tobacco